AN NING CHAO

Dr. AN NING CHAO

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2003 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
HDHakan Demirci
Hakan Demirci
CSCarol L Shields
Carol L Shields
ACAN NING CHAO
AN NING CHAO
JSJerry A Shields
Jerry A Shields

1 April 2015 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
Wei-Chi WuWei-Chi Wu
Wei-Chi Wu
RLReyin Lien
Reyin Lien
PLPei-Ju Liao
Pei-Ju Liao
NWNan-Kai Wang
Nan-Kai Wang
YCYen-Po Chen
Yen-Po Chen
CLChi-Chun Lai
Chi-Chun Lai
Retinopathy of prematurity (ROP) is one of the leading causes of blindness in very low-birth-weight premature infants. Previous studies1 have verified that the main pathologic growth factor mediating neovascularization and the development of ROP is vascular endothelial growth factor (VEGF). Identification of angiogenesis regulators has enabled the development of novel therapeutic approaches involving the use of anti-VEGF medications for the treatment of patients with stage 3 (proliferative) ROP.2,3

1 September 2012 in Ophthalmology
Verified
Journal Article
Closed access
Wei-Chi WuWei-Chi Wu
Wei-Chi Wu
RLRey-In Lin
Rey-In Lin
CSChia-Pang Shih
Chia-Pang Shih
Nan-Kai WangNan-Kai Wang
Nan-Kai Wang
YCYen-Po Chen
Yen-Po Chen
STShawn Tsai
Shawn Tsai

1 October 2001 in Ophthalmology
Verified
Journal Article
Closed access
ACAN NING CHAO
AN NING CHAO
CSCarol L Shields
Carol L Shields
HKHatem Krema
Hatem Krema
JSJerry A Shields
Jerry A Shields

1 April 2017 in Retina
Verified
Journal Article
Closed access
WWWei-Chi Wu
Wei-Chi Wu
CSChia-Pang Shih
Chia-Pang Shih
RLReyin Lien
Reyin Lien
NWNan-Kai Wang
Nan-Kai Wang
YCYen-Po Chen
Yen-Po Chen
CLChi-Chun Lai
Chi-Chun Lai
To investigate vascular endothelial growth factor (VEGF) levels in the systemic circulation after intravitreal injections of bevacizumab (IVB) or ranibizumab (IVR) in patients with Type 1 retinopathy of prematurity (ROP). Patients who had Type 1 ROP and received IVB or IVR were enrolled. Serum samples were collected before and up to 12 weeks after IVB or IVR treatment. The main outcome measurements were serum levels of VEGF up to 12 weeks after anti-VEGF treatment. In total, 10 patients with Type 1 ROP were enrolled in this study. All the eyes had complete resolution of abnormal neovascularization of ROP after IVB or IVR. In the direct comparison of IVB with IVR, serum VEGF was found to be suppressed more in patients with Type 1 ROP who received IVB treatment, compared with those who received IVR treatment (P = 0.01, P = 0.03, and P = 0.03, respectively, 2, 4, and 8 weeks after intravitreal injection). Serum VEGF levels in patients with Type 1 ROP were suppressed for 2 months after treatment with IVB, and VEGF levels were less affected after IVR treatment. Further studies are warranted to investigate the long-term effects of VEGF changes in ROP patients.

1 November 2013 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
Wei-Chi WuWei-Chi Wu
Wei-Chi Wu
CSChia-Pang Shih
Chia-Pang Shih
Nan-Kai WangNan-Kai Wang
Nan-Kai Wang
RLReyin Lien
Reyin Lien
YCYen-Po Chen
Yen-Po Chen
STShawn Tsai
Shawn Tsai
Retinopathy of prematurity (ROP) is one of the leading causes of childhood blindness. Children with a history of ROP have a lower visual acuity (VA) than full-term children despite a normal-appearing fundus. Our prior study using spectral-domain optical coherence tomography (SD-OCT) in patients with a history of ROP showed a thicker foveal thickness, higher incidence of absence of foveal depression, and retaining of inner retinal layers in patients with ROP compared with age-matched full-term children.1 These changes are associated with poor VA and high refractive errors in these patients.1